Contineum Therapeutics, Inc. Class A Common Stock (CTNM) — Capital Reinvestment Ratio
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a Capital Reinvestment Ratio of 0.00x as of June 2023, meaning it reinvests 0% of its operating cash flow ($40.67 Million) in capital expenditures ($31.00K). Check CTNM intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Contineum Therapeutics, Inc. Class A Common Stock Capital Reinvestment Ratio (2023–2023)
This chart tracks Contineum Therapeutics, Inc. Class A Common Stock's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see Contineum Therapeutics, Inc. Class A Com cash flow conversion.
Annual Capital Reinvestment Ratio for Contineum Therapeutics, Inc. Class A Common Stock (2023–2023)
Year-by-year Capital Reinvestment Ratio for Contineum Therapeutics, Inc. Class A Common Stock from 2023 to 2023. See CTNM free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 0.02x | $19.35 Million | $414.00K | — |